Inicio > SAINZ GIL, MARIA

SAINZ GIL, MARIA

PROFESOR AYUDANTE DOCTOR
Biología Celular, Histología y Farmacología
FARMACOGENÉTICA, GENÉTICA DEL CÁNCER, POLIMORFISMOS GENÉTICOS Y FARMACOEPIDEMIOLOGÍA
 
maria.sainz@uva.es
0

Índice H en Web of Science: 11
Índice H en Scopus: 10
 

[com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=626]]][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66718]], camposKey:1130-8621 2021-11-01 Reporting of suspected adverse drug reactions by nursing in Spain. An observational-descriptive retrospective study Notificación de sospechas de reacciones adversas a medicamentos por enfermeras en España. Un estudio observacional descriptivo retrospectivo363370, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66755]], camposKey:2045-2322 2021-10-07 A multicenter case-control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66521]], camposKey:0946-1965 2021-04-01 Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study280288, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56635]], camposKey:2047-9956 2021-01-01 A cross-sectional study of psychotropic drug use in the elderly: Consuming patterns, risk factors and potentially inappropriate use8893, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=64063]], camposKey:1130-8621 2021-01-01 Notificación de sospechas de reacciones adversas a medicamentos por enfermeras en España. Un estudio observacional descriptivo retrospectivo363370, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66756]], camposKey:0300-2896 2020-10-01 Hydroxychloroquine and Potential Drug Interactions in Older Adults679681, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56695]], camposKey:2210-7703 2020-01-01 Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases713720, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56637]], camposKey:1663-9812 2020-01-01 Corrigendum: Influence of Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study (Frontiers in Pharmacology, (2020), 11, 10.3389/fphar.2020.00860)00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56611]], camposKey:0300-2896 2020-01-01 Hydroxychloroquine and Potential Drug Interactions in Older Adults La hidroxicloroquina y las posibles interacciones farmacológicas en ancianos00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54298]], camposKey:0926-9959 2020-01-01 Kaposi sarcoma in patients on tumour necrosis factor alpha inhibitors: a case-noncase study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56636]], camposKey:1663-9812 2020-01-01 Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56811]], camposKey:1130-6343 2019-01-01 Medicamentos sujetos a seguimiento adicional en la Unión Europea1923, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41163]], camposKey:1130-6343 2019-01-01 Medicines under additional monitoring in the European Union Medicamentos sujetos a seguimiento adicional en la Unión Europea1923, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41160]], camposKey:0946-1965 2018-01-01 A polypharmacy risk prediction model for elderly patients based on sociodemographic and clinical factors577584, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41161]], camposKey:0165-1781 2018-01-01 Antipsychotics and cardiovascular risk: A case/non-case study341347, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40832]], camposKey:2210-7703 2018-01-01 Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study928935, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41162]], camposKey:1742-7835 2018-01-01 MEDICINES UNDER ADDITIONAL MONITORING: CRITERIA FOR INCLUSION, DISPENSATION CONDITIONS AND SAFETY6767, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56757]], camposKey:0114-5916 2017-01-01 Atypical Fracture of the Sternum After Long-Term Alendronate Plus Cholecalciferol Treatment: A Case Report00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3369]], camposKey:0025-7753 2017-01-01 Medication errors associated with oral administration of methotrexate. Data from spontaneous reporting and medical literature review Errores de medicación asociados a la administración oral de metotrexato. Datos de notificación espontánea y revisión de la bibliografía médica330332, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39773]], camposKey:0268-1315 2017-01-01 Risk excess of mortality and use of antipsychotics: a case-noncase study15, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3368]], camposKey:0264-410X 2017-01-01 Risk of bursitis and other injuries and dysfunctions of the shoulder following vaccinations48704876, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3370]], camposKey:1932-6203 2016-01-01 Carpal tunnel syndrome associated with oral bisphosphonates. A population-based cohort study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56696]], camposKey:2213-8587 2016-01-01 Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population507516, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=37]], camposKey:0033-3506 2016-01-01 Impact of regulatory measures on antipsychotics drug consumption in Castilla y Leon, Spain113119, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3371]], camposKey:1053-8569 2015-01-01 Emergency contraceptive pill safety profile. Comparison of the results of a follow-up study to those coming from spontaneous reporting9397, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=35]], camposKey:0264-410X 2015-01-01 Guillain-Barre syndrome and influenza vaccines: A meta-analysis37733778, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40043]], camposKey:1742-7835 2014-01-01 Facial paralysis and vaccines. A case non-case approach in vigibase and in vaers1616, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39774]], camposKey:0271-0749 2014-01-01 Hepatotoxicity Related to Agomelatine and Other New Antidepressants A Case/Noncase Approach With Information From the Portuguese, French, Spanish, and Italian Pharmacovigilance Systems327330, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43718]], camposKey:2385-409X 2014-01-01 Knowledge upon the emergency contraceptive pill in Spain224228, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40833]], camposKey:1139-7357 2014-01-01 Knowledge upon the emergency contraceptive pill in Spain224228, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39775]], camposKey:0767-3981 2014-01-01 No differences between men and women in adverse drug reactions related to psychotropic drugs: a survey from France, Italy and Spain342348, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40045]], camposKey:0114-5916 2013-01-01 Adverse Events Associated with Emergency Contraceptive: Comparing the Results of a Follow Up Study with Those Coming from Spontaneous Reporting874874, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39]], camposKey:0031-6970 2013-01-01 Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study559564, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56758]], camposKey:1742-7835 2013-01-01 PILOT STUDY OF PROBLEMS RELATED TO MEDICATIONS REPORTED BY CITIZENS2929, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40044]], camposKey:1742-7835 2013-01-01 Polypharmacy in highly dependent elderly patients: a series from Medora's electronical medical redords3030, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56759]], camposKey:0114-5916 2013-01-01 Preliminary Results for Reporting of Problems Associated with Medications in Spain. The yo notifico (I notify) Project840840, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=9199]], camposKey:1742-7835 2013-01-01 Weight Gain and Antipsychotics. A Case/non-case approach in vigibase88, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40046]], camposKey:1053-8569 2012-01-01 Dementia Mortality Rates and Cholinesterase Inhibitors Consumption in Castilla y Leon (Spain). An Ecologic Study7474, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=30]], camposKey:1742-7835 2012-01-01 MUSCULOSKELETAL SYMPTOMS ASSOCIATED WITH BISPHOSPHONATES. A RETROSPECTIVE FOLLOW-UP STUDY WITH INFORMATION FROM THE HEALTH IMPROVEMENT NETWORK (THIN)3536, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39776]], camposKey:1756-1841 2012-01-01 Severe pancytopenia following etanercept administration in rheumatoid arthritis00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3372]], camposKey:1053-8569 2012-01-01 Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): Changes in the consumption pattern following the introduction of extended release methylphenidate435441, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=9204]], camposKey:1053-8569 2012-01-01 Weight Gain Associated with Antipsychotics in a Naturalistic Setting: Icaro Study443443, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=38]], camposKey:0264-410X 2011-01-01 Adverse events associated with pandemic influenza vaccines: Comparison of the results of a follow-up study with those coming from spontaneous reporting519522, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40048]], camposKey:1053-8569 2011-01-01 Carpal Tunnel Syndrome Associated with Bisphosphonates. A Population-Based Cohort Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=16936]], camposKey:0210-5705 2011-01-01 Hepatitis colestásica por amoxicilina474477, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=9195]], camposKey:0114-5916 2011-01-01 Hepatotoxicity Associated with Agomelatine: A Case/Non-Case Study969970, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=33]], camposKey:1742-7835 2011-01-01 Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study3940, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=9197]], camposKey:0114-5916 2011-01-01 Selective Serotonin Reuptake Inhibitors and Gastrointestinal Bleeding: A Meta-Analysis944945, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3377]], camposKey:0009-9236 2010-01-01 Response to rupatadine and heart rhythm disturbances3738, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3376]], camposKey:1139-7357 2010-01-01 Study about antibiotic therapeutic compliance in pharmacy offices Estudio sobre cumplimiento terapéutico de antibióticos en oficinas de farmacia247250, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40831]], camposKey:0940-1334 2009-09-01 2nd European Conference on Schizophrenia Research: From Research to Practice Abstracts00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3378]], camposKey:1756-1833 2009-01-01 Drug Point: Strontium ranelate may cause alopecia12101210, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40]], camposKey:0009-9236 2009-01-01 Heart Rhythm Disturbances Associated With Rupatadine: A Case Series From the Spanish and Portuguese Pharmacovigilance Systems481484, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3380]], camposKey:0114-5916 2007-01-01 Gynaecomastia associated with proton pump inhibitors: A case series from the Spanish pharmacovigilance system527531, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=34]], camposKey:1742-7835 2006-01-01 Hepatic damage related to non-steroidal anti-inflammatory drugs. A case/non case study3333, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39772]], camposKey:0114-5916 2006-01-01 HMG CoA reductase inhibitors and impotence - Two case series from the Spanish and French drug monitoring systems143149, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=36]], camposKey:1742-7835 2006-01-01 New antidepressant drugs and upper gastrointestinal bleeding. A case-control study2323, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56772]], camposKey:1723-7807 2006-01-01 Recommendations for national registers of medicinal products with validated ATC codes and DDD values3035, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56762]], camposKey:1742-7835 2006-01-01 The genetic basis of some adverse effects. The eudragene project2626, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40834]], camposKey:0212-6567 2004-01-01 Use of Medication for Osteoporosis in Spain [2] Utilización de Medicamentos para la Osteoporosis en España [2]104105, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40830]], camposKey:1101-1262 2003-12-01 11th Annual EUPHA Meeting: program and abstracts7136, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56692]], camposKey:0025-7753 2003-01-01 Availability of drugs in the European Union. The case of antiplatelet agents [1][Oferta d medicamentos en la Unión Europa. El caso de los antiagregantes plaquetarios]793794, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39777]], camposKey:1101-1262 2003-01-01 EURO-MED-STAT - Monitoring expenditure and utilization of medicinal products in the European Union countries: a Public Health approach95100, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=13246]], camposKey:1135-5727 2003-01-01 Evolución del consumo de fármacos antipsicóticos en la Comunidad Autónoma de Castilla y León (1990-2001).725733, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3407]], camposKey:0025-7753 1992-01-01 The increase of the number of absences following exposition to amoxycillin/clavulanic acid [2] AUMENTO DEL NUMERO DE AUSENCIAS TRAS LA EXPOSICION A AMOXICILINA/ACIDO CLAVULANICO [2]793794][CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=14798]},camposKey: 93 120 La farmacovigilancia y los profesionales sanitarios 978-84-8317-830-0Los primeros 25 años del Sistema Español de Farmacovigilancia de Medicamentos de uso Humano 1 2010-01-01 Ediciones de la Universidad de Oviedo][com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=266]]][][com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=322]]][][com.sigma.fs3.argos.domain.gpc.Manuals[id=com.sigma.fs3.argos.domain.gpc.GpcManualsPK[ifcactivitat=MAN, ifccomptador=25]], com.sigma.fs3.argos.domain.gpc.Manuals[id=com.sigma.fs3.argos.domain.gpc.GpcManualsPK[ifcactivitat=MAN, ifccomptador=27]], com.sigma.fs3.argos.domain.gpc.Manuals[id=com.sigma.fs3.argos.domain.gpc.GpcManualsPK[ifcactivitat=MAN, ifccomptador=26]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62697]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62698]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62697]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62698]]][][][][][][][][][com.sigma.fs3.argos.domain.gpc.GpcComissioAssessor[id=com.sigma.fs3.argos.domain.gpc.GpcComissioAssessorPK[ifcactivitat=COM, ifccomptador=640]], com.sigma.fs3.argos.domain.gpc.GpcComissioAssessor[id=com.sigma.fs3.argos.domain.gpc.GpcComissioAssessorPK[ifcactivitat=COM, ifccomptador=506]]][GpcPartTribunals[ gpcPartTribunalsPK=GpcPartTribunalsPK[ ifcactivitat=PTR, ifccomptador=15 ] ]][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@19b42724, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@275b9ab, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@7ef08acf, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@62295d24, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@9a218d5, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@710c4ce3, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@5e8c0510, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@3aa08dee, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@2c62254, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@1df7ba38][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@4f06cc0a, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@473dcd0e, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@2a6176ac, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@64b62bf0, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@73fecd37, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@5d53115f, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@7899a3d6, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@7899a3d6][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3751f7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@37503d, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373595, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3739ca, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372c60, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@37268e, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372ae9, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372595, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@37258d][com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1759]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1758]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1757]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1760]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1761]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1762]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1763]]][com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1759]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1758]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1757]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1760]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1761]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1762]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=1763]]][][][][][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@414ec8], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@412f74], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41315d], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41314e], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45f179], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413732], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45f178], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413150], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@412c3e], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413c1e], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@412882], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@467bb8]][][][][]

PUBLICACIONES

Artículos de revista (65)


Enlace a la publicación
Ver Todos

Capítulos de libros (1)

Salgueiro, ME; Gil, MA; Jimeno FJ; Pérez B; Sáinz M; Esteban C. La farmacovigilancia y los profesionales sanitarios. En: Gloria Manso; Agustín Hidalgo; Alfonso Carvajal; Francisco José de Abajo. Los primeros 25 años del Sistema Español de Farmacovigilancia de Medicamentos de uso Humano. Ediciones de la Universidad de Oviedo; 2010. p. 93-120.


Ver Todos

Manuales y otras publicaciones del investigador/a (3)

Sainz Gil, María; Martín Arias, Luis H; Carvajal García-Pando, Alfonso. Boletín de la Tarjeta Amarilla nº 40. 2018.
Ver Todos
 

AYUDA A LA INVESTIGACIÓN

Proyectos (12)

OPTIMIZACIÓN DEL TRATAMIENTO FARMACOLÓGICO EN ANCIANOS POLIMEDICADOS A TRAVÉS DE UN ANÁLISIS FARMACOGENÉTICO. Equipo Investigadores: MARTIN ARIAS, LUIS HERMENEGILDO (IP); VERDE RELLO, ZORAIDA; SAINZ GIL, MARIA; JIMENO BULNES, NATALIA; VELASCO GONZALEZ, VERONICA; MINER PINO, CRISTINA; DURAN DOMINGUEZ, MARIA MERCEDES; SALADO VALDIVIESO, INES; VELASCO SAMPEDRO, ELADIO ANDRES. VA037G19. Entidades Participantes: UNIVERSIDAD DE VALLADOLID (UVa). Entidades Financiadoras: JUNTA DE CASTILLA Y LEÓN -CONSEJERÍA DE EDUCACIÓN. 10/07/2019-30/09/2021

JCYL-1
Ver Todos

Convenios (9)

SUBVENCION NOMINATIVA: FARMACOVIGILANCIA. Equipo Investigadores: MARTIN ARIAS, LUIS HERMENEGILDO (IP). Personal Contratado: SAINZ GIL, MARIA. Entidades Financiadoras: JUNTA DE CASTILLA Y LEÓN .-CONSEJERÍA DE SANIDAD.. 2017-11-01

Ver Todos

Otras ayudas y becas (2)

EUROPEAN COMMISSION PROGRMA MARCO EUROPEO FP5.. BECARIA EN EL PROYECTO: EUDRAGENE: EUROPEAN COLLABORAION TO ESTABLISH A CASE-CONTROL DNA COLLECTION FOR STUDYING THE GENETIC BASIS OF ADVERSE DRUG REACTION. REF.: QLRI-CT-2002-02757. INVESTIGADOR PRINCIPAL: PAUL McKEIGE. CARVAJAL GARCIA PANDO, ALFONSO (Director). SAINZ GIL, MARIA (Beneficiario). 01/01/2003 - 31/12/2006. 1.220.000,00 EUR.

Ver Todos
 

OTROS

Congresos (16)

III Jornada de Farmacovigilancia para la Red de Farmacias Centinela de Castilla y León, Valladolid ( ESPAÑA ) 22/03/2019 - 22/03/2019
(Mesa redonda). Sainz Gil, María. "Red de Farmacias Centinela de Castilla y León: experiencias, presentación de resultados e intervención en situaciones específicas"
(Asistencia). no aplicable. III Jornada de Farmacovigilancia para la Red de Farmacias Centinela de Castilla y León
Ver Todos

Organización de actos (8)

II JORNADAS DE FARMACOVIGILANCIA PARA LA RED DE FARMACIAS CENTINELA DE CASTILLA Y LEON, ZAMORA ( ESPAÑA ) 02/03/2018 -
Comité científico.
Ver Todos

Cursos y seminarios impartidos (7)

Farmacovigilancia. La ¿cara B¿ de los medicamentos: Farmacovigilancia. La "cara B" de los medicamentos. León 23/05/2018 - 23/05/2018
Ver Todos

Colaboración en revistas (1)

Revisor. European Journal of Clinical Pharmacology , 2018
Ver Todos

Participación en comités (2)

Comisión de seguimiento de la Red de Farmacias Centinela de Castilla y León. 01/06/2015
Ver Todos

Líneas de investigación (1)

FARMACOEPIDEMIOLOGÍA, FARMACOVIGILANCIA, FARMACOGENÉTICA
Ver Todos

Otras actividades (1)

31/05/2005, Grupo de Investigación Reconocido de la Universidad de Valladolid. Farmacogenética, Genética del cáncer, Polimorfismos genéticos y Farmacoepidemiología. LÍNEAS DE INVESTIGACIÓN: Polimorfismos Genéticos y Respuesta a Fármacos, Genética del Cáncer, Farmacoepidemiología.
Ver Todos
Cargando información ...
Universidad de Valladolid - Copyright Universidad de Valladolid - Todos los derechos reservados